Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Licensing Agreements 12
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14
Equity Offering 16
Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16
Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19
Newron Pharma to Raise Funds through Public Offering of Shares 21
Newron Pharma Announces Private Placement Of Shares For US$21 Million 22
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 24
Acquisition 25
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 25
Newron Pharmaceuticals SpA – Key Competitors 27
Newron Pharmaceuticals SpA – Key Employees 28
Newron Pharmaceuticals SpA – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Sep 13, 2018: Newron reports half-year 2018 results 30
Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018 32
Sep 14, 2017: Newron reports half-year 2017 results 35
Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017 37
Corporate Communications 38
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 38
Product News 39
10/25/2017: Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting 39
07/11/2017: XADAGO (Safinamide) Now Available in the U.S. for Parkinson’s Disease Patients 40
05/12/2017: Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago (safinamide) 41
04/10/2017: Zambon Launches Xadago (Safinamide) In Portugal For Patients With Mid- To Late-Stage Parkinson’s Disease 42
03/21/2017: FDA approves drug to treat Parkinson’s disease 43
03/02/2017: Newron Provides Update on Sarizotan 44
03/02/2017: Newron Pharmaceuticals Provides Update on Xadago (safinamide) 45
02/08/2018: Newron Pharmaceuticals Announces Change in the Board of Directors 46
02/01/2018: Primary Endpoint Met In Phase II/III Clinical Study of Investigational Parkinson’s Disease Treatment Safinamide in Japan 47
Product Approvals 48
Jun 12, 2017: Zambon’s Xadago Rejects For Use Within NHS Scotland 48
Clinical Trials 49
Jun 13, 2018: Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome 49
May 17, 2017: Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age 50
Other Significant Developments 51
Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018 51
Dec 11, 2017: Newron Provides End of Year Corporate Update 52
Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14
Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16
Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19
Newron Pharma to Raise Funds through Public Offering of Shares 21
Newron Pharma Announces Private Placement Of Shares For US$21 Million 22
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 24
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 25
Newron Pharmaceuticals SpA, Key Competitors 27
Newron Pharmaceuticals SpA, Key Employees 28
Newron Pharmaceuticals SpA, Subsidiaries 29
List of Figures
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9